Search International and National Patent Collections
Some content of this application is unavailable at the moment.
If this situation persists, please contact us atFeedback&Contact
1. (US20190202926) ANTI-DEATH RECEPTOR ANTIBODIES AND METHODS OF USE THEREOF

Office : United States of America
Application Number: 15780285 Application Date: 01.12.2016
Publication Number: 20190202926 Publication Date: 04.07.2019
Publication Kind : A1
Prior PCT appl.: Application Number:PCTEP2016079517 ; Publication Number: Click to see the data
IPC:
C07K 16/28
A61P 35/00
C07K 16/30
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
16
Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18
against material from animals or humans
28
against receptors, cell surface antigens or cell surface determinants
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35
Antineoplastic agents
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
16
Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18
against material from animals or humans
28
against receptors, cell surface antigens or cell surface determinants
30
from tumour cells
CPC:
A61P 35/00
C07K 16/2878
C07K 16/30
C07K 2317/526
A61K 38/00
C07K 2317/75
C07K 2317/31
C07K 2317/24
C07K 2317/73
Applicants: GENMAB B.V.
Inventors: Frank BEURSKENS
Marije OVERDIJK
Rob DE JONG
David SATIJN
Kristin STRUMANE
Janine SCHUURMAN
Paul PARREN
Priority Data: PA 2015 00771 01.12.2015 DK
PA 2015 00787 07.12.2015 DK
PA 2015 00788 07.12.2015 DK
PA 2016 00701 10.11.2016 DK
PA 2016 00702 10.11.2016 DK
Title: (EN) ANTI-DEATH RECEPTOR ANTIBODIES AND METHODS OF USE THEREOF
Abstract: front page image
(EN)

The present invention relates to monospecific or bispecific antibody molecules that specifically bind antigens of Death Receptors, which are members of the tumor necrosis factor (TNF) receptor Superfamily (TNFR-SF) with an intracellular death domain. The invention relates in particular to antibody molecules of the IgG1 isotype having a mutation in the Fc region that enhances clustering of IgG molecules after target binding. The invention further relates to a combination of antibody molecules binding different epitopes on one or more specific Death Receptors. The invention also relates to pharmaceutical compositions containing these molecules and the treatment of cancer using these compositions.


Also published as:
CA3007031EP3383905CN108884158BR112018011058WO/2017/093447